Elliptic Labs Launching on Upcoming vivo S19 and S19 Pro Smartphones
OSLO, Norway--(BUSINESS WIRE)--#AIVirtualProximitySensor--Elliptic Labs (OSE: ELABS), a global AI software company and the world leader…
2 years ago
Alex
DataRobot Collaborates with IMDA to Make LLM Evaluation More Accessible to AI Builders with Project Moonshot
New framework and set of capabilities for benchmarking and red teaming AI evaluation SINGAPORE--(BUSINESS WIRE)--DataRobot,…
2 years ago
ROBOTWORLD 2024 Presents Early Application Discount Promotions Until June
SEOUL, South Korea--(BUSINESS WIRE)--#KINTEX--ROBOTWORLD 2024, focusing on robotics from A to Z, is offering an…
2 years ago
Stampede Gold Comes Charging Onto Juicy Stakes Casino
What’s on offer online this week SYDNEY--(BUSINESS WIRE)--Out with the old and in with the…
2 years ago
Long-term future for New Zealand’s Tiwai Point aluminium smelter secured with new power deals
MELBOURNE, Australia--(BUSINESS WIRE)--New Zealand Aluminium Smelters (NZAS) has signed 20-year electricity arrangements that secure the…
2 years ago
Yatra Online, Inc. Announces Results for the Three Months and Year Ended March 31, 2024
GURUGRAM, India & NEW YORK--(BUSINESS WIRE)--$YTRA #AirTicketing--Yatra Online, Inc. (NASDAQ: YTRA) (the “Companyâ€), India’s leading…
2 years ago
Everybody Loves Languages Reports Financial Results for the First Quarter Ended March 31, 2024
TORONTO--(BUSINESS WIRE)--Everybody Loves Languages Corp. (“ELLâ€) (TSX-V: ELL; OTC: LMDCF; FSE: LIMA), www.everybodyloveslanguages.com, an edtech…
2 years ago
AEye CEO Matt Fisch to Keynote at Auto Lidar Tech Conference in Suzhou, China
Event hosted by DVN and Enmore scheduled for June 21, 2024 DUBLIN, Calif.--(BUSINESS WIRE)--AEye, Inc.…
2 years ago
Asia Pacific Prefabricated Construction Industry Report 2023-2027: Rising Inflation and Subsequent Surge in Material Prices to Support Growth – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Prefabricated Construction Industry Business and Investment Opportunities Databook - 100+ KPIs,…
2 years ago
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized…
2 years ago